Congenital heart disease affects one child for every 100 births. Abnormalities affecting the valvular structures are common in this group of patients. Current options for addressing these defects include repair or replacement with prosthetic valves. Current prosthetic valves have significant drawback for children. They do not grow, they calcify and degrade rapidly, and they may require systemic anticoagulation that is especially problematic in this age group.
The concept is that of a tubular Extracellular Matrix (ECM) valve replacement or creation. The cylinder (tube) is sutured to the valve annulus and to the papillary muscles within the left ventricle. The valve immediately functions as a mitral valve providing unidirectional flow from the left atrium to the ventricle. Over the course of several months the valve will be infiltrated with host cells that will slowly remodel it into a functional mitral valve.
APDC funds will be utilized for final design and development of the ECM mitral valve as well as the animal studies to be conducted at T3 Labs.